Brett Matthew Hall has bought IMRX on 2 days since Jun 2025

Brett Matthew Hall, Ph.D., is a Chief Scientific Officer and corporate insider at Immuneering Corporation (NASDAQ: IMRX), a clinical‑stage oncology company based in Cambridge, Massachusetts.( He has served as Immuneering’s Chief Scientific Officer since November 2019, leading the company’s scientific strategy and oncology drug development efforts.( As an insider, Hall has actively increased his ownership in Immuneering through multiple open‑market and employee stock purchase plan transactions, most recently acquiring 6,035 shares on June 15, 2026, bringing his direct holdings to 382,531 shares of Class A Common Stock.( In 2025 he was recognized as a “Leader of Influence in Life Sciences” by the San Diego Business Journal, underscoring his industry impact.(

Hall’s career spans leadership roles across biotechnology and large pharmaceutical companies, as well as academia and finance. Before joining Immuneering, he served as Chief Executive Officer of Asellus Therapeutics, Head of Translational Medicine, Oncology at MedImmune (AstraZeneca’s biologics division), and held positions of increasing responsibility at Johnson & Johnson, culminating as Head of Biomarkers, Hematologic Disease Area Stronghold, where he helped lead clinical translational efforts for Sylvant® and Imbruvica®.( He founded and chaired BioArkive, Inc., a privately held biotechnology services company, from January 2019 to December 2021.( Earlier, Hall was an Assistant Professor at The Ohio State University, focusing on tumor microenvironment–aligned models to improve clinical translation, and he has extensively published in tumor microenvironment and translational sciences while holding multiple patents in drug pharmacology and discovery.( He also previously served in the U.S. Air Force and worked as an investment banker.( Hall earned a B.S. in biochemistry from The Ohio State University, a Ph.D. in immunology and cancer biology from West Virginia University, and completed a post‑doctoral fellowship in cancer cell epigenetics at St. Jude Children’s Research Hospital.(

Written by Perplexity from public sources.